Mehra Uneek 4

4 · BridgeBio Oncology Therapeutics, Inc. · Filed Mar 12, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

BridgeBio Oncology (BBOT) CFO Uneek Mehra Receives Award Grants

What Happened

Uneek Mehra, Chief Financial Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), received equity awards on March 10, 2026: 23,330 restricted stock units (RSUs) and 105,000 derivative awards. Both grants were reported at $0.00 per share (typical for compensation awards) and are recorded as awards/grants (Form 4 code A).

Key Details

Transaction date and price: 2026-03-10; both awards reported at $0.00 per share.
RSU grant: 23,330 RSUs; settle in common stock upon vesting (see F1).
Derivative award: 105,000 units noted as a derivative award with a vesting schedule (see F2).
Vesting schedules (from filing footnotes):
- F1: RSUs vest in 16 equal quarterly installments over four years starting January 1, 2026; each RSU converts to one share when it vests.
- F2: The derivative award vests monthly in 1/48th increments starting January 1, 2026.
Shares owned after the transaction: Not specified in the provided filing excerpt.
Filing timeliness: Report filed 2026-03-12 for transactions on 2026-03-10 (appears timely under Form 4 reporting rules).

Context

These awards are compensation grants (not open-market purchases or sales). RSUs are contingent rights to receive shares only as they vest; derivative awards vest over time and may require exercise/settlement as specified by the plan. Such grants are commonly used for retention and incentive compensation and do not represent immediate cash proceeds or sales.

Form 4

Period: 2026-03-10

Chief Financial Officer

Transactions

Award
Common Stock
[F1]
2026-03-10+23,330→ 23,330 total
Award
Stock Option (Right to Buy)
[F2]
2026-03-10+105,000→ 105,000 total
Exercise: $10.19Exp: 2036-03-09→ Common Stock (105,000 underlying)

Footnotes (2)

[F1]Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.
[F2]1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Signature

/s/ Uneek Mehra|2026-03-12

1 file